NASDAQ:CNST - Constellation Pharmaceuticals Stock Price, Forecast & News

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Constellation Pharmaceuticals Inc (NASDAQ:CNST) announced its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.01. View Constellation Pharmaceuticals' Earnings History.

Constellation Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Constellation Pharmaceuticals.

5 brokers have issued 12 month price objectives for Constellation Pharmaceuticals' stock. Their forecasts range from $40.00 to $65.00. On average, they expect Constellation Pharmaceuticals' stock price to reach $50.40 in the next year. This suggests a possible upside of 28.0% from the stock's current price. View Analyst Price Targets for Constellation Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Constellation Pharmaceuticals.

Media stories about CNST stock have trended negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Constellation Pharmaceuticals earned a news impact score of -2.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Constellation Pharmaceuticals.

Constellation Pharmaceuticals saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 1,920,000 shares, an increase of 34.3% from the November 14th total of 1,430,000 shares. Based on an average daily trading volume, of 517,400 shares, the short-interest ratio is presently 3.7 days. Approximately 16.2% of the shares of the company are short sold. View Constellation Pharmaceuticals' Current Options Chain.

Some companies that are related to Constellation Pharmaceuticals include Ascendis Pharma A/S (ASND), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), FibroGen (FGEN), United Therapeutics (UTHR), Nektar Therapeutics (NKTR), Intercept Pharmaceuticals (ICPT), SAGE Therapeutics (SAGE), Blueprint Medicines (BPMC), Taro Pharmaceutical Industries (TARO), Evotec (EVTCY), Alkermes (ALKS), GW Pharmaceuticals PLC- (GWPH) and HUTCHISON CHINA/S (HCM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Biogen (BIIB), Lam Research (LRCX), Alibaba Group (BABA), Adobe (ADBE), Baidu (BIDU), NVIDIA (NVDA), Roku (ROKU), Chipotle Mexican Grill (CMG), Goldman Sachs Group (GS) and Snap (SNAP).

(CNST) raised $80 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

Constellation Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (0.75%), P.A.W. Capital Corp (0.62%), Alps Advisors Inc. (0.20%) and Barclays PLC (0.02%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Alexandria Venture Investments, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, James E Flynn, Of The University Of C Regents and Patrick Trojer. View Institutional Ownership Trends for Constellation Pharmaceuticals.

CNST stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Barclays PLC and State Street Corp. Company insiders that have sold Constellation Pharmaceuticals company stock in the last year include Adrian Senderowicz, Emma Reeve, James E Audia, Of The University Of C Regents and Patrick Trojer. View Insider Buying and Selling for Constellation Pharmaceuticals.

CNST stock was purchased by a variety of institutional investors in the last quarter, including P.A.W. Capital Corp. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Alexandria Venture Investments, Anthony B Evnin, Group L P Column and James E Flynn. View Insider Buying and Selling for Constellation Pharmaceuticals.

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CNST stock can currently be purchased for approximately $39.38.

Constellation Pharmaceuticals has a market capitalization of $1.32 billion. The company earns $-59,920,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe.View Additional Information About Constellation Pharmaceuticals.

The official website for Constellation Pharmaceuticals is http://www.constellationpharma.com/.

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]